Status:
TERMINATED
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
Lead Sponsor:
The Guthrie Clinic
Conditions:
Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated...
Eligibility Criteria
Inclusion
- Undergoing clinically indicated elective or non-elective PCI
- Able to swallow oral medications
Exclusion
- Contraindications to ticagrelor or fentanyl (or other opiates)
- Pregnancy
- Any use of P2Y12 inhibitors within 14 days
- Known coagulation disorders
- Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular weight heparin)
- Platelet count \< 100,000/mm3
- Impaired renal function (Estimated glomerular filtration \< 45 ml/min/1.73 m2)
- Impaired hepatic function (Based on medical history)
- Prior or planned transcatheter aortic valve replacement
Key Trial Info
Start Date :
April 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 23 2025
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03476369
Start Date
April 18 2018
End Date
January 23 2025
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Guthrie Clinic
Sayre, Pennsylvania, United States, 18840